• Users Online: 2551
  • Print this page
  • Email this page
Year : 2010  |  Volume : 54  |  Issue : 6  |  Page : 496-503

Role of human recombinant activated protein C and low dose corticosteroid therapy in sepsis

Department of Anaesthesia and Critical Care, ERA'S Lucknow Medical College, Lucknow, India

Correspondence Address:
Aparna Shukla
Department of Anaesthesia and Critical Care, Era's Lucknow Medical College, Lucknow
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0019-5049.72637

Rights and Permissions

Despite advances in modern medicine, sepsis remains a complex syndrome that has been associated with significant morbidity and mortality. Multiple organ failure associated with sepsis leads to high mortality and morbidity. About 28 - 50% deaths have been reported in patients with sepsis. The number of sepsis patients is increasing, with considerable burden on healthcare facilities. Various factors leading to a rise in the incidence of sepsis are (1) Improvement of diagnostic procedures (2) Increase in the number of immunocompromised patients taking treatment for various autoimmune disease, carcinomas, organ transplantation (3) Advances in intensive procedures (4) Nosocomial infections (5) Extensive use of antibiotics. With the better understanding of sepsis various modalities to modify pathophysiological response of septic patients have developed. Activated protein C and low-dose corticosteroid therapy have been tried in patients, with variable results.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded690    
    Comments [Add]    
    Cited by others 2    

Recommend this journal